CAS: 24722-30-3; Cyclohexanecarboximidamide

相似化合物

2498-48-8 1248947-50-3 162696-05-1

上下游产品

cyclohexane carbonitrile N-phenylcyclohexanecarboximidamide ammonia N-methylaniline2-cyclohexyl-4-phenyl-1H-imidazole 2-(cyclohexyl)-4,5-diphenyl-1H-imidazole 2,6-dichloro-2-cyclohexylpyrimidine 1-(3-cyclohexyl-[1,2,4]thiadiazol-5-yl)-4-[2-(4-methoxyphenyl)ethyl]piperazine

📜环己甲腈置于三甲基铝,氯化铵,水,Silica Gel体系中,用 甲苯,氯仿 用作溶剂,化学反应 2.0H,反应生成环己基甲脒
参考文献:Probing The Effect Of The Amidinium Group And The Phenyl Ring On The Thermodynamics Of Binding Of Benzamidinium Chloride To Trypsin
标题:Probing The Effect Of The Amidinium Group And The Phenyl Ring On The Thermodynamics Of Binding Of Benzamidinium Chloride To Trypsin
摘要:利用等温滴定量热法研究了脒基和苯基环对苯甲酰胺氯化物与丝氨酸蛋白酶胰蛋白酶结合热力学的影响.与苯甲酰胺氯化物,α-甲基苯甲酰胺氯化物和苯甲酰胺(与苯甲酰胺氯化物结构相关的化合物)的结合研究表明,脒基和酶之间的氢键结合主要是由焓驱动的.环己基氯化脒和氯化乙酰脒的结合表明,S1 袋中苯基环的疏水结合主要是由熵驱动的,抑制剂的刚性平坦疏水结合位点是有利的.在一定温度范围内研究的化合物在结合和焓熵补偿时表现出热容量的负变化,这都是疏水相互作用的特征.
Doi:10.1039/b410061A

专利信息

专利号:WO-9222662-A1
优先权日:1991-06-10
标 题:Methods for the synthesis of monofucosylated oligosaccharides terminating in di-n-acetyllactosaminyl structures
发明人：VENOT ANDRE P; KASHEM MOHAMMED A; SMITH RICHARD H
权利人:ALBERTA RES COUNCIL
摘要:Disclosed are methods for the preparation of monofucosylated and sialylated derivatives of the compound $g(b)Gal(1-4)$g(b)GlcNAc(1-3)$g(b)Gal(1-4)$g(b)GlcNAc-R. In particular, the methods of this invention provide for a multi-step synthesis wherein selective monofucosylation is accomplished on the 3-hydroxy group on only one of the GlcNAc units found in the $g(b)Gal(1-4)$g(b)GlcNAc(1-3)$g(b)Gal(1-4)$g(b)GlcNAc-R compound. In this step, monofucosylation is achieved by use of the $g(a)(1-3)fucosyltransferase.

专利号:EP-0591256-A1
优先权日:1991-06-10
标题 :Methods for the synthesis of monofucosylated oligosaccharides terminating in di-n-acetyllactosaminyl structures

专利号:US-10287617-B2
优先权日:2014-03-11
标题:Methods for in vitro—in vivo efficacy determination
发明人：KNUDSON SUSAN E; SLAYDEN RICHARD A
权利人:UNIV COLORADO STATE RES FOUND
摘要:The invention provides methods for determining and evaluating the in vitro-in vivo activity relationship of the efficacy of families of compounds for infectious diseases such as tuberculosis. The validity of the methods can be confirmed by evaluation of the compounds in animal models, for example, in murine models of tuberculosis. Examples of families of antibacterial compounds that can be evaluated for in vivo efficacy using the in vitro methods described herein include benzimidazoles, pyridopyrazines, pteridines, diphenyl ethers, beta-lactams, PBP inhibitors, and compounds that are non-ribonucleic acid and protein synthesis inhibitors. The methods can be used to evaluate classes of small molecule compounds and inhibitors that may be effective against any bacterial pathogen. The methods aid the identification of compounds, such as various benzimidazoles, with modes of action having activity against clinical isolates, as well as non-replicating persistent bacilli, which can therefore enhance current clinical therapeutic regimens.